BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29844011)

  • 1. USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism.
    Melo-Cardenas J; Xu Y; Wei J; Tan C; Kong S; Gao B; Montauti E; Kirsammer G; Licht JD; Yu J; Ji P; Crispino JD; Fang D
    Blood; 2018 Jul; 132(4):423-434. PubMed ID: 29844011
    [No Abstract]   [Full Text] [Related]  

  • 2. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
    Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
    Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.
    Zhang J; Wang J; Liu Y; Sidik H; Young KH; Lodish HF; Fleming MD
    Blood; 2009 Feb; 113(6):1304-14. PubMed ID: 19066392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease.
    Aydin E; Hallner A; Grauers Wiktorin H; Staffas A; Hellstrand K; Martner A
    Oncogene; 2019 Feb; 38(9):1534-1543. PubMed ID: 30323311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aggressive transformation of juvenile myelomonocytic leukemia associated with duplication of oncogenic KRAS due to acquired uniparental disomy.
    Kato M; Yasui N; Seki M; Kishimoto H; Sato-Otsubo A; Hasegawa D; Kiyokawa N; Hanada R; Ogawa S; Manabe A; Takita J; Koh K
    J Pediatr; 2013 Jun; 162(6):1285-8, 1288.e1. PubMed ID: 23403250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique dependence on Sos1 in
    You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
    Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia.
    Zhao S; Zhang Y; Sha K; Tang Q; Yang X; Yu C; Liu Z; Sun W; Cai L; Xu C; Cui S
    Cell Physiol Biochem; 2014; 33(1):78-87. PubMed ID: 24480914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
    Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
    J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of Gastric Cancer by Successive Oncogenic Activation in the Corpus.
    Douchi D; Yamamura A; Matsuo J; Melissa Lim YH; Nuttonmanit N; Shimura M; Suda K; Chen S; Pang S; Kohu K; Abe T; Shioi G; Kim G; Shabbir A; Srivastava S; Unno M; Bok-Yan So J; Teh M; Yeoh KG; Chuang LSH; Ito Y
    Gastroenterology; 2021 Dec; 161(6):1907-1923.e26. PubMed ID: 34391772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of c-myc gene accompanied by PU.1 deficiency in radiation-induced acute myeloid leukemia in mice.
    Hirouchi T; Takabatake T; Yoshida K; Nitta Y; Nakamura M; Tanaka S; Ichinohe K; Oghiso Y; Tanaka K
    Exp Hematol; 2008 Jul; 36(7):871-85. PubMed ID: 18375040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells.
    Steidl U; Rosenbauer F; Verhaak RG; Gu X; Ebralidze A; Otu HH; Klippel S; Steidl C; Bruns I; Costa DB; Wagner K; Aivado M; Kobbe G; Valk PJ; Passegué E; Libermann TA; Delwel R; Tenen DG
    Nat Genet; 2006 Nov; 38(11):1269-77. PubMed ID: 17041602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide CRISPR Screen to Identify Genes that Suppress Transformation in the Presence of Endogenous Kras
    Huang J; Chen M; Xu ES; Luo L; Ma Y; Huang W; Floyd W; Klann TS; Kim SY; Gersbach CA; Cardona DM; Kirsch DG
    Sci Rep; 2019 Nov; 9(1):17220. PubMed ID: 31748650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kras mutations and PU.1 promoter methylation are new pathways in murine radiation-induced AML.
    O'Brien G; Cruz-Garcia L; Zyla J; Brown N; Finnon R; Polanska J; Badie C
    Carcinogenesis; 2020 Aug; 41(8):1104-1112. PubMed ID: 31646336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.
    Okayama H; Saito M; Oue N; Weiss JM; Stauffer J; Takenoshita S; Wiltrout RH; Hussain SP; Harris CC
    Int J Cancer; 2013 Jan; 132(1):9-18. PubMed ID: 22618808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice.
    Ye H; Zhang C; Wang BJ; Tan XH; Zhang WP; Teng Y; Yang X
    Oncogene; 2014 Oct; 33(43):5133-8. PubMed ID: 24213574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
    Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
    Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
    Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
    Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PU.1 promotes cell cycle exit in the murine myeloid lineage associated with downregulation of E2F1.
    Ziliotto R; Gruca MR; Podder S; Noel G; Ogle CK; Hess DA; DeKoter RP
    Exp Hematol; 2014 Mar; 42(3):204-217.e1. PubMed ID: 24316397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blastic transformation of juvenile myelomonocytic leukemia caused by the copy number gain of oncogenic KRAS.
    Osumi T; Kato M; Ouchi-Uchiyama M; Tomizawa D; Kataoka K; Fujii Y; Seki M; Takita J; Ogawa S; Uchiyama T; Ohki K; Kiyokawa N
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28244637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic
    Osswald L; Hamarsheh S; Uhl FM; Andrieux G; Klein C; Dierks C; Duquesne S; Braun LM; Schmitt-Graeff A; Duyster J; Boerries M; Brummer T; Zeiser R
    Mol Cancer Res; 2021 Sep; 19(9):1596-1608. PubMed ID: 34088868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.